Volumetry after botulinum toxin A: the impact on abdominal wall compliance and endotracheal pressure.
Abstract
[PURPOSE] Botulinum toxin type A (BTA) is an adjuvant tool used in the preoperative optimization of complex hernias before abdominal wall reconstruction (AWR). This study aims to investigate changes in the abdominal cavity and hernia sac dimensions after BTA application.
[METHOD] A prospective study with 27 patients with a hernia defect of ≥ 10 cm and loss of domain (LOD) ≥ 20% underwent AWR. Computed tomography (CT) measurements and volumetry before and after the application of BTA were performed. Intraoperative and postoperative outcomes were evaluated.
[RESULTS] Imaging post-BTA revealed hernia width reduction of 1.9 cm (p = 0.002), lateral abdominal wall muscle elongation of 3.1 cm (p < 0.001), hernia volume reduction (HV) from 2.9 ± 0.9L to 2.4 ± 0.8L (p < 0.001), increase in abdominal cavity volume (ACV) from 9.7 ± 2.5L to 10.3L ± 2.4L (p = 0.003), and a reduction in the HV/ACV ratio from 30.2 ± 5% to 23.4 ± 6% (p < 0.001). Fascial closure was achieved in 92.6% of cases and component separation was required in 78%. The average variation in pulmonary plateau pressure was 3.53 cmHO, and there were no postoperative respiratory failure recorded. At the 90-day follow-up, the wound morbidity rate was 25%, unplanned readmissions were 11%, and hernia recurrence 7.4%.
[CONCLUSION] BTA produces measurable volumetric changes in abdominal wall and appears to facilitate fascial closure. Further studies are required to determine the role of BTA in the surgical armamentarium for complex hernia repair.
[METHOD] A prospective study with 27 patients with a hernia defect of ≥ 10 cm and loss of domain (LOD) ≥ 20% underwent AWR. Computed tomography (CT) measurements and volumetry before and after the application of BTA were performed. Intraoperative and postoperative outcomes were evaluated.
[RESULTS] Imaging post-BTA revealed hernia width reduction of 1.9 cm (p = 0.002), lateral abdominal wall muscle elongation of 3.1 cm (p < 0.001), hernia volume reduction (HV) from 2.9 ± 0.9L to 2.4 ± 0.8L (p < 0.001), increase in abdominal cavity volume (ACV) from 9.7 ± 2.5L to 10.3L ± 2.4L (p = 0.003), and a reduction in the HV/ACV ratio from 30.2 ± 5% to 23.4 ± 6% (p < 0.001). Fascial closure was achieved in 92.6% of cases and component separation was required in 78%. The average variation in pulmonary plateau pressure was 3.53 cmHO, and there were no postoperative respiratory failure recorded. At the 90-day follow-up, the wound morbidity rate was 25%, unplanned readmissions were 11%, and hernia recurrence 7.4%.
[CONCLUSION] BTA produces measurable volumetric changes in abdominal wall and appears to facilitate fascial closure. Further studies are required to determine the role of BTA in the surgical armamentarium for complex hernia repair.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 2 | |
| 해부 | sac
|
scispacy | 1 | ||
| 해부 | BTA
→ Botulinum toxin type A
|
scispacy | 1 | ||
| 해부 | pulmonary
|
scispacy | 1 | ||
| 합병증 | abdominal wall
|
scispacy | 1 | ||
| 합병증 | endotracheal
|
scispacy | 1 | ||
| 합병증 | abdominal cavity
|
scispacy | 1 | ||
| 합병증 | hernia
|
scispacy | 1 | ||
| 합병증 | wound
|
scispacy | 1 | ||
| 약물 | ± 0.9L
|
scispacy | 1 | ||
| 약물 | ACV
→ abdominal cavity volume
|
scispacy | 1 | ||
| 약물 | ± 2.5L
|
scispacy | 1 | ||
| 약물 | [PURPOSE] Botulinum toxin type A
|
scispacy | 1 | ||
| 약물 | 0.8L
|
scispacy | 1 | ||
| 약물 | HV/ACV
|
scispacy | 1 | ||
| 약물 | [CONCLUSION] BTA
|
scispacy | 1 | ||
| 질환 | hernias
|
C0019270
Hernia
|
scispacy | 1 | |
| 질환 | AWR
→ abdominal wall reconstruction
|
C0198542
Abdominoplasty (procedure)
|
scispacy | 1 | |
| 질환 | hernia
|
C0019270
Hernia
|
scispacy | 1 | |
| 질환 | volume reduction
|
scispacy | 1 | ||
| 질환 | respiratory failure
|
C1145670
Respiratory Failure
|
scispacy | 1 | |
| 질환 | BTA
→ Botulinum toxin type A
|
scispacy | 1 | ||
| 기타 | abdominal wall
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | BTA
→ Botulinum toxin type A
|
scispacy | 1 | ||
| 기타 | lateral abdominal wall muscle
|
scispacy | 1 | ||
| 기타 | fascial
|
scispacy | 1 |
MeSH Terms
Humans; Abdominal Wall; Botulinum Toxins, Type A; Hernia, Ventral; Prospective Studies; Herniorrhaphy; Abdominal Muscles; Surgical Mesh; Recurrence
📑 인용 관계
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.